; onclick=)
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/lanreotide-uses-dosage-side-effects-interaction_250813.jpg?fit=800%2C600&ssl=1" class="aligncenter wp-post-image" alt="" decoding="async" srcset="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/lanreotide-uses-dosage-side-effects-interaction_250813.jpg?w=800&ssl=1 800w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/lanreotide-uses-dosage-side-effects-interaction_250813.jpg?resize=768%2C576&ssl=1 768w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/lanreotide-uses-dosage-side-effects-interaction_250813.jpg?resize=360%2C270&ssl=1 360w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/lanreotide-uses-dosage-side-effects-interaction_250813.jpg?resize=600%2C450&ssl=1 600w" sizes="(max-width: 800px) 100vw, 800px" data-attachment-id="255458" data-permalink="https://rxharun.com/rxharun/drug-a-z/lanreotide/attachment/lanreotide-uses-dosage-side-effects-interaction/" data-orig-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/lanreotide-uses-dosage-side-effects-interaction_250813.jpg?fit=800%2C600&ssl=1" data-orig-size="800,600" data-comments-opened="0" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Lanreotide – Uses, Dosage, Side Effects, Interaction" data-image-description="" data-image-caption="" data-medium-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/lanreotide-uses-dosage-side-effects-interaction_250813.jpg?fit=800%2C600&ssl=1" data-large-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/lanreotide-uses-dosage-side-effects-interaction_250813.jpg?fit=800%2C600&ssl=1" data-jpibfi-post-excerpt="" data-jpibfi-post-url="https://rxharun.com/rxharun/drug-a-z/lanreotide/" data-jpibfi-post-title="Lanreotide – Uses, Dosage, Side Effects, Interaction" data-jpibfi-src="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/lanreotide-uses-dosage-side-effects-interaction_250813.jpg?fit=800%2C600&ssl=1">
Lanreotide is a synthetic polypeptide analog of somatostatin that resembles the native hormone in its ability to suppress levels and activity of growth hormone, insulin, glucagon, and many other gastrointestinal peptides. Because its half-life is longer than somatostatin, lanreotide can be used clinically to treat neuroendocrine tumors that secrete excessive amounts of growth hormone (acromegaly) or other active hormones or neuropeptides. Lanreotide has many side effects including suppression of gall bladder contractility and bile production, and maintenance therapy may cause cholelithiasis and pancreatitis as well accompanying liver injury.
Lanreotide Acetate is the acetate salt of a synthetic cyclic octapeptide analog of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2, and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I). This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.
Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I). This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.
Lanreotide Acetate is the acetate salt of a synthetic cyclic octapeptide analog of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2, and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I). This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.
Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, Ipsen Pharmaceuticals as lanreotide acetate, and marketed as Somatuline. It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.
Mechanism of Action
Lanreotide is a somatostatin analog (SSA) and has mainly inhibitory effects which are mediated via somatostatin receptors (SSTRs) 2 and 5 and include inhibition of growth hormone release in the brain. Tumor SSTR activation induces downstream cell cycle arrest and/or apoptosis, and also results in blunted production of substances that support tumor growth as well as tumor angiogenesis. This leads to the antiproliferative effects of Lanreotide.
Lanreotide exhibits antisecretory effects through cAMP suppression and activation of ion currents such as K+ and Ca2+ which leads to hyperpolarization of the membrane and inhibition of Ca2+-mediated depolarization. Furthermore, through direct and indirect mechanisms, Lanreotide has potent antiproliferative effects.
Indications
- Lanreotide is indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to, or cannot be treated with, surgery and/or radiotherapy. It is also indicated in the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced, or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. Lanreotide is additionally indicated for the treatment of adults with carcinoid syndrome – when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.
- Lanreotide is a somatostatin analog used for the treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors and acromegaly.
- Treatment of acromegaly, Treatment of gastrointestinal fistulae, Treatment of metastases to the peritoneum, Treatment of pituitary gigantism, Treatment of pituitary neoplasms
- Lanreotide is a synthetic polypeptide analog of somatostatin that resembles the native hormone in its ability to suppress levels and activity of growth hormone, insulin, glucagon, and many other gastrointestinal peptides. Because its half-life is longer than somatostatin, lanreotide can be used clinically to treat neuroendocrine tumors that secrete excessive amounts of growth hormone (acromegaly) or other active hormones or neuropeptides.
- Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors, and VIPomas. In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma,[rx] a rare tumor of the pituitary gland which secretes TSH. Lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogs, is being studied as a possible general antitumor agent.
- Acromegaly
- Carcinoid Syndrome
- Unresectable, locally advanced enteropancreatic neuroendocrine tumors
- Unresectable, locally advanced well- or moderately-differentiated Gastroenteropancreatic Neuroendocrine Tumors
- Unresectable, metastatic enteropancreatic neuroendocrine tumors
- Unresectable, metastatic well- or moderately-differentiated Gastroenteropancreatic Neuroendocrine Tumors
Use in Cancer
Lanreotide acetate is approved to treat:
- Gastroenteropancreatic neuroendocrine tumors. It is used in some adults whose tumors cannot be removed by surgery, is locally advanced, or have metastasized (spread to other parts of the body).
- Carcinoid syndrome in adults.
Lanreotide acetate is also being studied in the treatment of other conditions or types of cancer.
Contraindications
- Bradycardia, cardiac disease. Use lanreotide with caution in patients with underlying cardiac disease or preexisting bradycardia.
- Diabetes mellitus.
- Gallbladder disease.
- Hepatic disease.
- Hypothyroidism, thyroid disease.
- Pregnancy.
- Infertility, reproductive risk.
- Breast-feeding.
- a condition with low thyroid hormone levels
- low blood sugar
- high blood pressure
- slow heartbeat
- liver problems
- gallstones
- disease of the gallbladder
- high blood sugar
- a patient who is producing milk and breastfeeding
- chronic kidney disease stage 3A (moderate)
- chronic kidney disease stage 3B (moderate)
- chronic kidney disease stage 4 (severe)
- chronic kidney disease stage 5 (failure)
- kidney disease with likely reduction in kidney function
Dosage
Strengths: 60 mg/0.2 mL; 90 mg/0.3 mL; 120 mg/0.5 mL
Acromegaly
- Initial dose: 90 mg, by deep subcutaneous injection, every 4 weeks for 3 months
- The goal of treatment is to reduce growth hormone (GH) and insulin-like growth factor (IGF-1) levels to normal.
- Adjust dose after initial 3 months.
- No dose adjustment is required for elderly patients.
- Long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.
Neuroendocrine Carcinoma
- 120 mg, by deep subcutaneous injection, every 4 weeks
- No dose adjustment is required for elderly patients.
- Treatment of patients with unresectable, well or moderately-differentiated, locally advanced, or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.
Carcinoid Syndrome
- 120 mg by deep subcutaneous injection every 4 weeks
- If patients are already being treated for GEP-NETs, do not administer an additional dose for the treatment of carcinoid syndrome.
- For the treatment of carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.
Renal Dose Adjustments
Acromegaly:
- Moderate to severe renal impairment: Initial dose: 60 mg, by deep subcutaneous injection, every 4 weeks for 3 months, followed by dose adjustments as described for non-really impaired patients.
- Use caution when considering an extended dosing interval (120 mg every 6 or 8 weeks) in moderate or severe renal impairment.
Gastroenteropancreatic Neuroendocrine Tumors:
- No adjustment is recommended for mild to moderate renal impairment
- Data not available for severe renal impairment
Liver Dose Adjustments
Acromegaly:
- Moderate to severe hepatic impairment: Initial dose: 60 mg, by deep subcutaneous injection, every 4 weeks for 3 months, followed by dose adjustments as described for non-hepatically impaired patients.
Gastroenteropancreatic Neuroendocrine Tumors:
- Data not available for any level of hepatic impairment
Dose Adjustments
Acromegaly:
After the initial 3 month dosing, adjust dose based on growth hormone (GH) and insulin-like growth factor (IGF-1) levels:
- GH over 1 and up to 2.5 ng/mL, IGF-1 normal, and symptoms controlled: 90 mg, by deep subcutaneous (SC) injection, every 4 weeks
- GH over 2.5 ng/mL, IGF-1 elevated, and/or symptoms uncontrolled: 120 mg, by deep SC injection, every 4 weeks
- GH less than 1 ng/mL, IGF-1 normal, symptoms controlled: 60 mg, by deep SC injection, every 4 weeks
- Adjust dose according to patient response, as judged by a reduction in GH and/or IGF-1 levels, and/or changes in acromegaly symptoms.
- Patients controlled on 60 mg or 90 mg may be considered for an extended dosing interval of 120 mg every 6 or 8 weeks; obtain GH and IGF-1 levels 6 weeks after this change to evaluate persistence of patient response.
- Continued monitoring of patient response with dose adjustments for biochemical and clinical symptom control, as necessary, is recommended.
- No dose adjustment is required for elderly patients.
- No difference in safety and effectiveness was seen in elderly patients, however greater sensitivity cannot be ruled out.
- In general, dose selection for elderly patient should be cautious, starting at the low end of the dosing range.
- No dose adjustment is required for elderly patients.
Administration advice:
- Healthcare providers should administer this drug.
- Administer in the superior external quadrant of the buttock; alternate between right and left sides with each injection.
- Remove from refrigerator 30 minutes before administration, but keep pouch sealed until ready to administer.
Side Effects
The Most Common
- diarrhea
- loose stools
- constipation
- gas
- vomiting
- weight loss
- headache
- redness, pain, itching, or a lump at the injection site
- depression
- pain in the upper right part of the stomach, center of the stomach, back, or shoulder
- muscle pain or discomfort
- yellowing of the skin and eyes
- fever with chills
- nausea
- swelling of the face, throat, tongue, lips, or eyes
- tightness in the throat
- difficulty breathing and swallowing
- wheezing
- hoarseness
- rash
- itching
- hives
- shortness of breath
- slowed or irregular heartbeat
More common
- Blurred vision
- chest pain or discomfort
- dizziness
- gaseous abdominal or stomach pain
- headache
- lightheadedness, dizziness, or fainting
- nervousness
- pale skin
- pounding in the ears
- recurrent fever
- slow, fast, or irregular heartbeat
- stomach fullness
- troubled breathing with exertion
- unusual bleeding or bruising
- unusual tiredness or weakness
- yellow eyes or skin
- Difficulty having a bowel movement
- difficulty with moving
- excess air or gas in the stomach or bowels
- feeling of fullness
- inflammation, itching, lumps, or pain at the injection site
- muscle pain or stiffness
- pain in the joints
- passing gas
- weight loss
Rare
- Bloating
- chills
- clay-colored stools
- confusion
- constipation
- cough
- dark urine
- diarrhea
- difficulty swallowing
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- fat in the stool
- fever
- hives, itching, skin rash
- indigestion
- large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
- loss of appetite
- nausea
- pains in the stomach, side, or abdomen, possibly radiating to the back
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- severe nausea or vomiting
- stomach pain or cramps
- sudden loss of weight
- sweating
- tightness in the chest
- unusual drowsiness, dullness, or feeling of sluggishness
- vomiting
Drug Interactions
| DRUG | INTERACTION |
|---|---|
| Abemaciclib | The metabolism of Abemaciclib can be decreased when combined with Lanreotide. |
| Acalabrutinib | The metabolism of Acalabrutinib can be decreased when combined with Lanreotide. |
| Acarbose | The therapeutic efficacy of Acarbose can be decreased when used in combination with Lanreotide. |
| Acebutolol | Acebutolol may increase the bradycardic activities of Lanreotide. |
| Acenocoumarol | The serum concentration of Acenocoumarol can be increased when it is combined with Lanreotide. |
| Acetohexamide | The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lanreotide. |
| Albendazole | The metabolism of Albendazole can be decreased when combined with Lanreotide. |
| Albiglutide | The therapeutic efficacy of Albiglutide can be decreased when used in combination with Lanreotide. |
| Alectinib | The metabolism of Alectinib can be decreased when combined with Lanreotide. |
| Alfentanil | Alfentanil may increase the bradycardic activities of Lanreotide. |
| Alfuzosin | The metabolism of Alfuzosin can be decreased when combined with Lanreotide. |
| Alogliptin | The therapeutic efficacy of Alogliptin can be decreased when used in combination with Lanreotide. |
| Alpelisib | The metabolism of Alpelisib can be decreased when combined with Lanreotide. |
| Alprazolam | The metabolism of Alprazolam can be decreased when combined with Lanreotide. |
| Aminophylline | The metabolism of Aminophylline can be decreased when combined with Lanreotide. |
| Amiodarone | The metabolism of Amiodarone can be decreased when combined with Lanreotide. |
| Amlodipine | Amlodipine may increase the bradycardic activities of Lanreotide. |
| Aripiprazole | The metabolism of Aripiprazole can be decreased when combined with Lanreotide. |
| Aripiprazole | The metabolism of Aripiprazole lauroxil can be decreased when combined with Lanreotide. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Articaine. |
| Astemizole | The metabolism of Astemizole can be decreased when combined with Lanreotide. |
| Atazanavir | The metabolism of Atazanavir can be decreased when combined with Lanreotide. |
| Atenolol | Atenolol may increase the bradycardic activities of Lanreotide. |
| Atorvastatin | The metabolism of Atorvastatin can be decreased when combined with Lanreotide. |
| Axitinib | The metabolism of Axitinib can be decreased when combined with Lanreotide. |
| Azithromycin | The metabolism of Azithromycin can be decreased when combined with Lanreotide. |
| Bendroflumethi | Bendroflumethiazide may increase the bradycardic activities of Lanreotide. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Benzocaine. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Benzyl alcohol. |
| Bepridil | Bepridil may increase the bradycardic activities of Lanreotide. |
| Beractant | Beractant may increase the bradycardic activities of Lanreotide. |
| Betaxolol | Betaxolol may increase the bradycardic activities of Lanreotide. |
| Bicalutamide | The metabolism of Bicalutamide can be decreased when combined with Lanreotide. |
| Bisoprolol | Bisoprolol may increase the bradycardic activities of Lanreotide. |
| Bortezomib | The metabolism of Bortezomib can be decreased when combined with Lanreotide. |
| Bosutinib | The metabolism of Bosutinib can be decreased when combined with Lanreotide. |
| Brentuximab vedotin | The metabolism of Brentuximab vedotin can be decreased when combined with Lanreotide. |
| Bretylium | Bretylium may increase the bradycardic activities of Lanreotide. |
| Brigatinib | The metabolism of Brigatinib can be decreased when combined with Lanreotide. |
| Bromocriptine | The serum concentration of Bromocriptine can be increased when it is combined with Lanreotide. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Bupivacaine. |
| Busulfan | The metabolism of Busulfan can be decreased when combined with Lanreotide. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Butacaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Butamben. |
| Cabazitaxel | The metabolism of Cabazitaxel can be decreased when combined with Lanreotide. |
| Cabergoline | The metabolism of Cabergoline can be decreased when combined with Lanreotide. |
| Calfactant | Calfactant may increase the bradycardic activities of Lanreotide. |
| Canagliflozin | The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lanreotide. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Capsaicin. |
| Carbamazepine | The metabolism of Carbamazepine can be decreased when combined with Lanreotide. |
| Carvedilol | Carvedilol may increase the bradycardic activities of Lanreotide. |
| Celiprolol | Celiprolol may increase the bradycardic activities of Lanreotide. |
| Cephalexin | The metabolism of Cephalexin can be decreased when combined with Lanreotide. |
| Ceritinib | Lanreotide may increase the bradycardic activities of Ceritinib. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Chloroprocaine. |
| Chlorpromazine | The metabolism of Chlorpromazine can be decreased when combined with Lanreotide. |
| Chlorpropamide | The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lanreotide. |
| Cilostazol | The metabolism of Cilostazol can be decreased when combined with Lanreotide. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Cinchocaine. |
| Cinnarizine | Cinnarizine may increase the bradycardic activities of Lanreotide. |
| Cisapride | The metabolism of Cisapride can be decreased when combined with Lanreotide. |
| Citalopram | The risk or severity of hypoglycemia can be increased when Citalopram is combined with Lanreotide. |
| Clevidipine | Clevidipine may increase the bradycardic activities of Lanreotide. |
| Clomipramine | The metabolism of Clomipramine can be decreased when combined with Lanreotide. |
| Clonidine | The metabolism of Clonidine can be decreased when combined with Lanreotide. |
| Clozapine | The serum concentration of Clozapine can be increased when it is combined with Lanreotide. |
| Cobimetinib | The metabolism of Cobimetinib can be decreased when combined with Lanreotide. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Cocaine. |
| Colchicine | The metabolism of Colchicine can be decreased when combined with Lanreotide. |
| Conivaptan | The metabolism of Conivaptan can be decreased when combined with Lanreotide. |
| Copanlisib | The metabolism of Copanlisib can be decreased when combined with Lanreotide. |
| Copper oxodotre | The therapeutic efficacy of Lanreotide can be decreased when used in combination with Copper oxodotreotide Cu-64. |
| Crizotinib | Crizotinib may increase the bradycardic activities of Lanreotide. |
| Cyclandelate | Cyclandelate may increase the bradycardic activities of Lanreotide. |
| Cyclophosphamide | The metabolism of Cyclophosphamide can be decreased when combined with Lanreotide. |
| Cyclosporine | The bioavailability of Cyclosporine can be decreased when combined with Lanreotide. |
| Dabrafenib | The metabolism of Dabrafenib can be decreased when combined with Lanreotide. |
| Dacomitinib | The metabolism of Dacomitinib can be decreased when combined with Lanreotide. |
| Dapagliflozin | The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Lanreotide. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lanreotide. |
| Dasatinib | The metabolism of Dasatinib can be decreased when combined with Lanreotide. |
| Desvenlafaxine | The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Lanreotide. |
| Dexmedetomidine | Dexmedetomidine may increase the bradycardic activities of Lanreotide. |
| Digitoxin | The metabolism of Digitoxin can be decreased when combined with Lanreotide. |
| Digoxin | Digoxin may increase the bradycardic activities of Lanreotide. |
| Dihydroergocornine | The metabolism of Dihydroergocornine can be decreased when combined with Lanreotide. |
| Dihydroergocristine | The metabolism of Dihydroergocristine can be decreased when combined with Lanreotide. |
| Dihydroergotamine | The metabolism of Dihydroergotamine can be decreased when combined with Lanreotide. |
| Diltiazem | Diltiazem may increase the bradycardic activities of Lanreotide. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Diphenhydramine. |
| Disopyramide | The therapeutic efficacy of Disopyramide can be decreased when used in combination with Lanreotide. |
| Docetaxel | The metabolism of Docetaxel can be decreased when combined with Lanreotide. |
| Dofetilide | The metabolism of Dofetilide can be decreased when combined with Lanreotide. |
| Donepezil | Donepezil may increase the bradycardic activities of Lanreotide. |
| Dotatate gallium | Lanreotide may decrease effectiveness of Dotatate gallium Ga-68 as a diagnostic agent. |
| Doxazosin | The metabolism of Doxazosin can be decreased when combined with Lanreotide. |
| Doxorubicin | The metabolism of Doxorubicin can be decreased when combined with Lanreotide. |
| Dronabinol | The serum concentration of Dronabinol can be increased when it is combined with Lanreotide. |
| Dronedarone | The metabolism of Dronedarone can be decreased when combined with Lanreotide. |
| Drospirenone | The metabolism of Drospirenone can be decreased when combined with Lanreotide. |
| Dulaglutide | The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lanreotide. |
| Duloxetine | The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Lanreotide. |
| Duvelisib | The metabolism of Duvelisib can be decreased when combined with Lanreotide. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Dyclonine. |
| Ebastine | The metabolism of Ebastine can be decreased when combined with Lanreotide. |
| Edotreotide | Lanreotide may decrease effectiveness of Edotreotide gallium Ga-68 as a diagnostic agent. |
| Elexacaftor | The metabolism of Elexacaftor can be decreased when combined with Lanreotide. |
| Eliglustat | The metabolism of Eliglustat can be decreased when combined with Lanreotide. |
| Empagliflozin | The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lanreotide. |
| Enasidenib | The metabolism of Enasidenib can be decreased when combined with Lanreotide. |
| Entrectinib | The metabolism of Entrectinib can be decreased when combined with Lanreotide. |
| Enzalutamide | The serum concentration of Enzalutamide can be increased when it is combined with Lanreotide. |
| Erdafitinib | The metabolism of Erdafitinib can be decreased when combined with Lanreotide. |
| Ergotamine | The metabolism of Ergotamine can be decreased when combined with Lanreotide. |
| Erlotinib | The metabolism of Erlotinib can be decreased when combined with Lanreotide. |
| Ertugliflozin | The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Lanreotide. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Lanreotide. |
| Escitalopram | The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Lanreotide. |
| Esmolol | Esmolol may increase the bradycardic activities of Lanreotide. |
| Estetrol | The metabolism of Estetrol can be decreased when combined with Lanreotide. |
| Eszopiclone | The metabolism of Eszopiclone can be decreased when combined with Lanreotide. |
| Ethosuximide | Ethosuximide may increase the bradycardic activities of Lanreotide. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Etidocaine. |
| Etoposide | The metabolism of Etoposide can be decreased when combined with Lanreotide. |
| Everolimus | The metabolism of Everolimus can be decreased when combined with Lanreotide. |
| Exenatide | The therapeutic efficacy of Exenatide can be decreased when used in combination with Lanreotide. |
| Felodipine | Felodipine may increase the bradycardic activities of Lanreotide. |
| Fenofibrate | The metabolism of Fenofibrate can be decreased when combined with Lanreotide. |
| Fentanyl | Fentanyl may increase the bradycardic activities of Lanreotide. |
| Fexinidazole | The risk or severity of adverse effects can be increased when Lanreotide is combined with Fexinidazole. |
| Finerenone | The serum concentration of Finerenone can be increased when it is combined with Lanreotide. |
| Fingolimod | Lanreotide may increase the bradycardic activities of Fingolimod. |
| Flunarizine | Flunarizine may increase the bradycardic activities of Lanreotide. |
| Fluoxetine | The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Lanreotide. |
| Fluspirilene | Fluspirilene may increase the bradycardic activities of Lanreotide. |
| Fluvoxamine | The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Lanreotide. |
| Fosaprepitant | The metabolism of Fosaprepitant can be decreased when combined with Lanreotide. |
| Fosphenytoin | The metabolism of Fosphenytoin can be decreased when combined with Lanreotide. |
| Galantamine | Galantamine may increase the bradycardic activities of Lanreotide. |
| Gatifloxacin | The risk or severity of hypoglycemia can be increased when Gatifloxacin is combined with Lanreotide. |
| Gilteritinib | The metabolism of Gilteritinib can be decreased when combined with Lanreotide. |
| Gliclazide | The therapeutic efficacy of Gliclazide can be decreased when used in combination with Lanreotide. |
| Glimepiride | The therapeutic efficacy of Glimepiride can be decreased when used in combination with Lanreotide. |
| Glipizide | The therapeutic efficacy of Glipizide can be decreased when used in combination with Lanreotide. |
| Gliquidone | The therapeutic efficacy of Gliquidone can be decreased when used in combination with Lanreotide. |
| Glyburide | The therapeutic efficacy of Glyburide can be decreased when used in combination with Lanreotide. |
| Glymidine | The therapeutic efficacy of Glymidine can be decreased when used in combination with Lanreotide. |
| Guanfacine | Guanfacine may increase the bradycardic activities of Lanreotide. |
| Haloperidol | The serum concentration of Haloperidol can be increased when it is combined with Lanreotide. |
| Ibrutinib | The metabolism of Ibrutinib can be decreased when combined with Lanreotide. |
| Idelalisib | The metabolism of Idelalisib can be decreased when combined with Lanreotide. |
| Ifosfamide | The metabolism of Ifosfamide can be decreased when combined with Lanreotide. |
| Iloperidone | The metabolism of Iloperidone can be decreased when combined with Lanreotide. |
| Indomethacin | The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Lanreotide. |
| Infigratinib | The metabolism of Infigratinib can be decreased when combined with Lanreotide. |
| Insulin aspart | The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin aspart. |
| Insulin beef | The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin beef. |
| Insulin degludec | The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin degludec. |
| Insulin detemir | The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin detemir. |
| Insulin glargine | The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin glargine. |
| Insulin glulisine | The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin glulisine. |
| Insulin human | The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin human. |
| Insulin lispro | The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin lispro. |
| Insulin pork | The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin pork. |
| Irinotecan | The metabolism of Irinotecan can be decreased when combined with Lanreotide. |
| Isavuconazole | The metabolism of Isavuconazole can be decreased when combined with Lanreotide. |
| Isradipine | Isradipine may increase the bradycardic activities of Lanreotide. |
| Ivabradine | Lanreotide may increase the bradycardic activities of Ivabradine. |
| Ivosidenib | The metabolism of Ivosidenib can be decreased when combined with Lanreotide. |
| Ixabepilone | The metabolism of Ixabepilone can be decreased when combined with Lanreotide. |
| Ixazomib | The metabolism of Ixazomib can be decreased when combined with Lanreotide. |
| Labetalol | Labetalol may increase the bradycardic activities of Lanreotide. |
| Lacidipine | Lanreotide may increase the bradycardic activities of Lacidipine. |
| Lacosamide | Lacosamide may increase the bradycardic activities of Lanreotide. |
| Lamotrigine | Lamotrigine may increase the bradycardic activities of Lanreotide. |
| Lasmiditan | Lasmiditan may increase the bradycardic activities of Lanreotide. |
| Lefamulin | The metabolism of Lefamulin can be decreased when combined with Lanreotide. |
| Lercanidipine | Lercanidipine may increase the bradycardic activities of Lanreotide. |
| Levacetylmethadol | The metabolism of Levacetylmethadol can be decreased when combined with Lanreotide. |
| Levamlodipine | The serum concentration of Levamlodipine can be increased when it is combined with Lanreotide. |
| Levobetaxolol | Lanreotide may increase the bradycardic activities of Levobetaxolol. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Levobupivacaine. |
| Levomenthol | Levomenthol may increase the bradycardic activities of Lanreotide. |
| Levomilnacipran | The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Levomilnacipran. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Lidocaine. |
| Lidoflazine | Lanreotide may increase the bradycardic activities of Lidoflazine. |
| Linagliptin | The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lanreotide. |
| Lipoic acid | The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Lanreotide. |
| Liraglutide | The therapeutic efficacy of Liraglutide can be decreased when used in combination with Lanreotide. |
| Lixisenatide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Lanreotide. |
| Lomitapide | The metabolism of Lomitapide can be decreased when combined with Lanreotide. |
| Loperamide | Loperamide may increase the bradycardic activities of Lanreotide. |
| Lovastatin | The metabolism of Lovastatin can be decreased when combined with Lanreotide. |
| Lucinactant | Lucinactant may increase the bradycardic activities of Lanreotide. |
| Lutetium Lu | The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Lanreotide. |
| Macimorelin | The therapeutic efficacy of Macimorelin can be decreased when used in combination with Lanreotide. |
| Magnesium sulfate | Magnesium sulfate may increase the bradycardic activities of Lanreotide. |
| Manidipine | Lanreotide may increase the bradycardic activities of Manidipine. |
| Mecasermin | The therapeutic efficacy of Mecasermin can be decreased when used in combination with Lanreotide. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Meloxicam. |
| Meperidine | The metabolism of Meperidine can be decreased when combined with Lanreotide. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Mepivacaine. |
| Metformin | The therapeutic efficacy of Metformin can be decreased when used in combination with Lanreotide. |
| Methotrexate | The metabolism of Methotrexate can be decreased when combined with Lanreotide. |
| Methoxy | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lanreotide. |
| Methsuximide | Methsuximide may increase the bradycardic activities of Lanreotide. |
| Methyldopa | Methyldopa may increase the bradycardic activities of Lanreotide. |
| Methylprednisone | The metabolism of Methylprednisone can be decreased when combined with Lanreotide. |
| Methysergide | The metabolism of Methysergide can be decreased when combined with Lanreotide. |
| Metoprolol | Metoprolol may increase the bradycardic activities of Lanreotide. |
| Midazolam | The serum concentration of Midazolam can be increased when it is combined with Lanreotide. |
| Midodrine | Midodrine may increase the bradycardic activities of Lanreotide. |
| Midostaurin | The metabolism of Midostaurin can be decreased when combined with Lanreotide. |
| Mifepristone | The therapeutic efficacy of Mifepristone can be decreased when used in combination with Lanreotide. |
| Miglitol | The therapeutic efficacy of Miglitol can be decreased when used in combination with Lanreotide. |
| Milnacipran | The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Lanreotide. |
| Nadolol | Nadolol may increase the bradycardic activities of Lanreotide. |
| Nateglinide | The therapeutic efficacy of Nateglinide can be decreased when used in combination with Lanreotide. |
| Nebivolol | Nebivolol may increase the bradycardic activities of Lanreotide. |
| Nefazodone | The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Lanreotide. |
| Neratinib | The metabolism of Neratinib can be decreased when combined with Lanreotide. |
| Netupitant | The metabolism of Netupitant can be decreased when combined with Lanreotide. |
| Nicardipine | Nicardipine may increase the bradycardic activities of Lanreotide. |
| Nifedipine | Nifedipine may increase the bradycardic activities of Lanreotide. |
| Nilotinib | The metabolism of Nilotinib can be decreased when combined with Lanreotide. |
| Nilvadipine | Nilvadipine may increase the bradycardic activities of Lanreotide. |
| Nimesulide | Nimesulide may increase the bradycardic activities of Lanreotide. |
| Nimodipine | Nimodipine may increase the bradycardic activities of Lanreotide. |
| Nintedanib | The metabolism of Nintedanib can be decreased when combined with Lanreotide. |
| Nisoldipine | Nisoldipine may increase the bradycardic activities of Lanreotide. |
| Nitrendipine | Nitrendipine may increase the bradycardic activities of Lanreotide. |
| Norethisterone | The metabolism of Norethisterone can be decreased when combined with Lanreotide. |
| Nortriptyline | The metabolism of Nortriptyline can be decreased when combined with Lanreotide. |
| Nylidrin | Nylidrin may increase the bradycardic activities of Lanreotide. |
| Octreotide | The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Lanreotide. |
| Olaparib | The metabolism of Olaparib can be decreased when combined with Lanreotide. |
| Osimertinib | The metabolism of Osimertinib can be decreased when combined with Lanreotide. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Oxetacaine. |
| Oxprenolol | Oxprenolol may increase the bradycardic activities of Lanreotide. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Oxybuprocaine. |
| Paclitaxel | The metabolism of Paclitaxel can be decreased when combined with Lanreotide. |
| Palbociclib | The metabolism of Palbociclib can be decreased when combined with Lanreotide. |
| Panobinostat | The metabolism of Panobinostat can be decreased when combined with Lanreotide. |
| Paroxetine | The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Lanreotide. |
| Pasireotide | The risk or severity of hypoglycemia can be increased when Pasireotide is combined with Lanreotide. |
| Pazopanib | The metabolism of Pazopanib can be decreased when combined with Lanreotide. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Lanreotide. |
| Pegvisomant | The risk or severity of increased transaminases can be increased when Lanreotide is combined with Pegvisomant. |
| Penbutolol | Penbutolol may increase the bradycardic activities of Lanreotide. |
| Pentamidine | The therapeutic efficacy of Pentamidine can be decreased when used in combination with Lanreotide. |
| Perhexiline | Perhexiline may increase the bradycardic activities of Lanreotide. |
| Pexidartinib | The metabolism of Pexidartinib can be decreased when combined with Lanreotide. |
| Phenformin | The therapeutic efficacy of Phenformin can be decreased when used in combination with Lanreotide. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Phenol. |
| Phenprocoumon | The metabolism of Phenprocoumon can be decreased when combined with Lanreotide. |
| Pimavanserin | The metabolism of Pimavanserin can be decreased when combined with Lanreotide. |
| Pimozide | The metabolism of Pimozide can be decreased when combined with Lanreotide. |
| Pinaverium | Lanreotide may increase the bradycardic activities of Pinaverium. |
| Pindolol | Pindolol may increase the bradycardic activities of Lanreotide. |
| Pioglitazone | The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lanreotide. |
| Pomalidomide | The metabolism of Pomalidomide can be decreased when combined with Lanreotide. |
| Ponatinib | The metabolism of Ponatinib can be decreased when combined with Lanreotide. |
| Ponesimod | The risk or severity of bradycardia can be increased when Ponesimod is combined with Lanreotide. |
| Poractant alfa | Lanreotide may increase the bradycardic activities of Poractant alfa. |
| Practolol | Practolol may increase the bradycardic activities of Lanreotide. |
| Pramlintide | The therapeutic efficacy of Pramlintide can be decreased when used in combination with Lanreotide. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Pramocaine. |
| Pregabalin | The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Lanreotide. |
| Prenylamine | Prenylamine may increase the bradycardic activities of Lanreotide. |
| Pretomanid | The metabolism of Pretomanid can be decreased when combined with Lanreotide. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Prilocaine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Procaine. |
| Propafenone | Propafenone may increase the bradycardic activities of Lanreotide. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Proparacaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Propoxycaine. |
| Propranolol | Propranolol may increase the bradycardic activities of Lanreotide. |
| Prucalopride | The metabolism of Prucalopride can be decreased when combined with Lanreotide. |
| Quinidine | The metabolism of Quinidine can be decreased when combined with Lanreotide. |
| Quinine | The therapeutic efficacy of Quinine can be decreased when used in combination with Lanreotide. |
| Regorafenib | The metabolism of Regorafenib can be decreased when combined with Lanreotide. |
| Remifentanil | Remifentanil may increase the bradycardic activities of Lanreotide. |
| Repaglinide | The therapeutic efficacy of Repaglinide can be decreased when used in combination with Lanreotide. |
| Retapamulin | The metabolism of Retapamulin can be decreased when combined with Lanreotide. |
| Ribociclib | The metabolism of Ribociclib can be decreased when combined with Lanreotide. |
| Rivastigmine | Rivastigmine may increase the bradycardic activities of Lanreotide. |
| Roflumilast | The serum concentration of Roflumilast can be increased when it is combined with Lanreotide. |
| Romidepsin | The metabolism of Romidepsin can be decreased when combined with Lanreotide. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Ropivacaine. |
| Rosiglitazone | The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Lanreotide. |
| Rosuvastatin | The metabolism of Rosuvastatin can be decreased when combined with Lanreotide. |
| Ruxolitinib | Ruxolitinib may increase the bradycardic activities of Lanreotide. |
| Saxagliptin | The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Lanreotide. |
| Semaglutide | The therapeutic efficacy of Semaglutide can be decreased when used in combination with Lanreotide. |
| Sertraline | The risk or severity of hypoglycemia can be increased when Sertraline is combined with Lanreotide. |
| Siponimod | The metabolism of Siponimod can be decreased when combined with Lanreotide. |
| Sirolimus | The metabolism of Sirolimus can be decreased when combined with Lanreotide. |
| Sitagliptin | The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Lanreotide. |
| Sonidegib | The metabolism of Sonidegib can be decreased when combined with Lanreotide. |
| Sorafenib | The metabolism of Sorafenib can be decreased when combined with Lanreotide. |
| Sotagliflozin | The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Lanreotide. |
| Sotalol | Sotalol may increase the bradycardic activities of Lanreotide. |
| Sufentanil | Sufentanil may increase the bradycardic activities of Lanreotide. |
| Sulfadiazine | The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Lanreotide. |
| Sulfamethoxazole | The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Lanreotide. |
| Sulfisoxazole | The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Lanreotide. |
| Sunitinib | The metabolism of Sunitinib can be decreased when combined with Lanreotide. |
| Suvorexant | The metabolism of Suvorexant can be decreased when combined with Lanreotide. |
| Tacrolimus | The serum concentration of Tacrolimus can be increased when it is combined with Lanreotide. |
| Tamoxifen | The metabolism of Tamoxifen can be decreased when combined with Lanreotide. |
| Tasimelteon | The metabolism of Tasimelteon can be decreased when combined with Lanreotide. |
| Tazemetostat | The metabolism of Tazemetostat can be decreased when combined with Lanreotide. |
| Temsirolimus | The metabolism of Temsirolimus can be decreased when combined with Lanreotide. |
| Teniposide | The metabolism of Teniposide can be decreased when combined with Lanreotide. |
| Tenofovir alafen | The metabolism of Tenofovir alafenamide can be decreased when combined with Lanreotide. |
| Terfenadine | The metabolism of Terfenadine can be decreased when combined with Lanreotide. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Tetracaine. |
| Theophylline | The metabolism of Theophylline can be decreased when combined with Lanreotide. |
| Thiotepa | The metabolism of Thiotepa can be decreased when combined with Lanreotide. |
| Timolol | Timolol may increase the bradycardic activities of Lanreotide. |
| Tirzepatide | The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Lanreotide. |
| Tizanidine | Tizanidine may increase the bradycardic activities of Lanreotide. |
| Tofacitinib | The metabolism of Tofacitinib can be decreased when combined with Lanreotide. |
| Tolazamide | The therapeutic efficacy of Tolazamide can be decreased when used in combination with Lanreotide. |
| Tolbutamide | The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Lanreotide. |
| Tolfenamic acid | Lanreotide may increase the bradycardic activities of Tolfenamic acid. |
| Tolvaptan | The metabolism of Tolvaptan can be decreased when combined with Lanreotide. |
| Trabectedin | The metabolism of Trabectedin can be decreased when combined with Lanreotide. |
| Tramadol | The metabolism of Tramadol can be decreased when combined with Lanreotide. |
| Trastuzumab | The metabolism of Trastuzumab emtansine can be decreased when combined with Lanreotide. |
| Trimebutine | Lanreotide may increase the bradycardic activities of Trimebutine. |
| Trimethadione | Trimethadione may increase the bradycardic activities of Lanreotide. |
| Troglitazone | The therapeutic efficacy of Troglitazone can be decreased when used in combination with Lanreotide. |
| Ubidecarenone | The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Ubidecarenone. |
| Ubrogepant | The serum concentration of Ubrogepant can be increased when it is combined with Lanreotide. |
| Vandetanib | The metabolism of Vandetanib can be decreased when combined with Lanreotide. |
| Vardenafil | The metabolism of Vardenafil can be decreased when combined with Lanreotide. |
| Vemurafenib | The metabolism of Vemurafenib can be decreased when combined with Lanreotide. |
| Venetoclax | The metabolism of Venetoclax can be decreased when combined with Lanreotide. |
| Venlafaxine | The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Lanreotide. |
| Verapamil | Verapamil may increase the bradycardic activities of Lanreotide. |
| Vildagliptin | The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lanreotide. |
| Vinblastine | The metabolism of Vinblastine can be decreased when combined with Lanreotide. |
| Vincristine | The metabolism of Vincristine can be decreased when combined with Lanreotide. |
| Vindesine | The metabolism of Vindesine can be decreased when combined with Lanreotide. |
| Vinflunine | The metabolism of Vinflunine can be decreased when combined with Lanreotide. |
| Vinorelbine | The metabolism of Vinorelbine can be decreased when combined with Lanreotide. |
| Vorapaxar | The metabolism of Vorapaxar can be decreased when combined with Lanreotide. |
| Voxelotor | The serum concentration of Voxelotor can be increased when it is combined with Lanreotide. |
| Warfarin | The serum concentration of Warfarin can be increased when it is combined with Lanreotide. |
| Zanubrutinib | The metabolism of zanubrutinib can be decreased when combined with Lanreotide. |
| Zimelidine | The risk or severity of hypoglycemia can be increased when Zimelidine is combined with Lanreotide. |
| Ziprasidone | The metabolism of Ziprasidone can be decreased when combined with Lanreotide. |
| Zonisamide | Zonisamide may increase the bradycardic activities of Lanreotide. |
| Zopiclone | The metabolism of Zopiclone can be decreased when combined with Lanreotide. |
| Zuclopenthixol | The metabolism of Zuclopenthixol can be decreased when combined with Lanreotide. |
Pregnancy and Lactation
AU TGA pregnancy category: C
US FDA pregnancy category: Not assigned
Pregnancy
Limited available data based on post-marketing case reports with lanreotide use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. In animal reproduction studies, decreased embryo/fetal survival was observed in pregnant rats and rabbits at subcutaneous doses 5- and 2-times the maximum recommended human dose (MRHD) of 120 mg, respectively (see Data). The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to
20%, respectively.
Lactation
There is no information available on the presence of lanreotide in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Studies show that lanreotide administered subcutaneously passes into the milk of lactating rats; however,
due to specifies-specific differences in lactation physiology, animal data may not reliably predict drug levels in human milk. Because of the potential for serious adverse reactions in breastfed infants from Lanreotide Injection, including effects on glucose metabolism and
bradycardia, advise women not to breastfeed during treatment with Lanreotide Injection and for 6 months (6 half-lives) following the last dose.
Why is this medication prescribed?
Lanreotide injection is used to treat people with acromegaly (a condition in which the body produces too much growth hormone, causing enlargement of the hands, feet, and facial features; joint pain; and other symptoms) who have not successfully, or cannot be treated with surgery or radiation. Lanreotide injection is also used to treat people with neuroendocrine tumors in the gastrointestinal (GI) tract or the pancreas (GEP-NETs) that have spread or cannot be removed by surgery. Lanreotide injection is in a class of medications called somatostatin agonists. It works by decreasing the amounts of certain natural substances produced by the body.
How should this medicine be used?
Lanreotide comes as a long-acting solution (liquid) to be injected subcutaneously (under the skin) into the upper outer area of your buttock by a doctor or nurse. Lanreotide long-acting injection is usually injected once every 4 weeks. Ask your doctor or pharmacist to explain any part you do not understand.
Your doctor will probably adjust your dose or the length of time between doses depending on your lab results. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What special precautions should I follow?
Before receiving lanreotide injection,
- tell your doctor and pharmacist if you are allergic to lanreotide injection, any other medications, or any of the ingredients in lanreotide injection. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: beta-blockers such as atenolol (Tenormin, in Tenoretic), labetalol (Trandate), metoprolol (Lopressor, Toprol XL, in Dutoprol), nadolol (Corgard, in Corzide), and propranolol (Hemangeol, Inderal, InnoPran); bromocriptine (Cycloset, Parlodel); cyclosporine (Gengraf, Neoral, Sandimmune); insulin and oral medications for diabetes; quinidine (in Nuedexta), or terfenadine (no longer available in the U.S.). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor if you have or have ever had diabetes, or gallbladder, heart, kidney, thyroid, or liver disease.
- tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while receiving a lanreotide injection, call your doctor.
- you should know that lanreotide injection may make you drowsy or dizzy. Do not drive a car or operate machinery until you know how this medication affects you.
References
